Telaprevir increases cure rate in hepatitis C study

05/26/2010 | New York Times (tiered subscription model), The

Hepatitis C drug telaprevir reduced the virus to an undetectable level in 75% of clinical-trial patients who received the standard dose in combination with interferon and ribavirin, Vertex Pharmaceuticals reported. The study focused on patients with Genotype 1 hepatitis C who had not received treatment before the trial.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance & Ethics, US Operations
Bristol-Myers Squibb
Princeton, NJ
Manager, Educational Programs
The Food and Drug Law Institute
Washington, DC, DC
Global Medical Safety Director - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Compliance Manager/Sr. Compliance Manager- Auditing
Genentech
South San Francisco, CA